Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01950910 · ClinicalTrials.gov registry record
Establishment of a Tissue Bank (Blood, CSF) for the Understanding of Motor Neuron Disease (MND)
A clinical trial, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- 766
- Enrollment target
NCT01950910: Clinical Trial study, sponsored by Wake Forest University Health Sciences.
NCT01950910 is a clinical trial that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 766 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01950910 was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- 766 participants
- Enrollment target
Study Summary
Biomarkers are essential for the identification of disease states. There are no early diagnostic or prognostic markers for ALS. The purpose of this study is to identify a panel of biomarkers from blood or spinal fluid of ALS patients and to collect data to better understand disease progression.
Primary Outcome
Blood samples will be processed to obtain serum samples and to isolate peripheral blood mononuclear cells (PBMC's). Serum samples will be analyzed for biochemical and metabolic markers of interest and future cell culture as needed. PBMCs will be processed for RNA, DNA or protein isolation. Aliquots of all samples will be stored for future study.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 766 participants |
| Start Date | 2004-03-29 |
| Est. Completion | 2020-10-29 |
Why NCT01950910 stopped before completion
NCT01950910 is an observational study that tracks outcomes without assigning an intervention. The registered 766 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01950910 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01950910 about?
NCT01950910 is a clinical study titled "Establishment of a Tissue Bank (Blood, CSF) for the Understanding of Motor Neuron Disease (MND)". Biomarkers are essential for the identification of disease states. There are no early diagnostic or prognostic markers for ALS. The purpose of this study is to identify a panel of biomarkers from blood or spinal fluid of ALS patients and to collect data to better understand disease progression.
What is the current status of trial NCT01950910?
This trial is currently terminated. The enrollment target is 766 participants. The study started on 2004-03-29. Estimated completion is 2020-10-29.
Who is sponsoring clinical trial NCT01950910?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07195591 · 766 participants · Phase 3
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
- NCT03789552 · 765 participants · Phase 3
Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina
- NCT05119556 · 768 participants · NA
Video Telehealth Pulmonary Rehabilitation to Reduce Hospital Readmission in Chronic Obstructive Pulmonary Disease
- NCT05404750 · 768 participants
Harm Reduction in HIV Primary Care for PLWH Who Use Drugs
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI